

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7639415

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY	10/25/2022
RECEIVING PARTY DATA	
Name:	SHANGHAI YIDIAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD.
Street Address:	ROOM 102, 1F, BUILDING 12, NO. 1835 DUHUI ROAD
Internal Address:	MINHANG DISTRICT
City:	SHANGHA
State/Country:	CHINA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14400508
CORRESPONDENCE DATA	
Fax Number:	(510)663-0920
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	510-663-1100
Email:	SJoshi@wavsip.com
Correspondent Name:	WEAVER AUSTIN VILLENEUVE & SAMPSON LLP
Address Line 1:	P.O. BOX 70250
Address Line 4:	OAKLAND, CALIFORNIA 94612-0250
ATTORNEY DOCKET NUMBER:	XUPTP008US
NAME OF SUBMITTER:	SWAPNALI JOSHI
SIGNATURE:	/Swapnali Joshi/
DATE SIGNED:	11/10/2022
Total Attachments: 3	
source=XUPTP008US_Executed_Assignment_ECU-SYPTD#page1.tif	
source=XUPTP008US_Executed_Assignment_ECU-SYPTD#page2.tif	
source=XUPTP008US_Executed_Assignment_ECU-SYPTD#page3.tif	

ASSIGNMENT OF PATENTS**Parties:**

- (1) **EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY**, a Chinese Corporation having an address of No. 130 Mellong Road, Xuhui District, Shanghai 200237, China (the '**Assignor**'); and
- (2) **Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.**, a Chinese limited company with a place of business at Room 102, 1F, Building 12, No. 1835 Duhui Road, Minhang District, Shanghai, China (the '**Assignee**');

Together the '**parties**' or each a '**party**' as the context may indicate.

Whereas:

The Assignor is the owner of the inventions (the '**Inventions**'), which are the subject matter of the patent applications set out in the schedule to this assignment (the '**Patents**').

IT IS AGREED as follows:**1. Assignment**

In consideration of the sum of Euro 1.00 (receipt and sufficiency of which the Assignor expressly acknowledges), the Assignor hereby assigns to the Assignee absolutely all of its right, title and interest in, to and arising from the Inventions and the Patents and the Assignee hereby accepts such assignment and transfer for all countries designated, such that the Assignee is hereafter the proprietor of the Inventions and the Patents, including (without limitation):

- (a) In respect of any and each application in the Patents:
 - (i) the right to claim priority from the Patents;
 - (ii) the right to file and prosecute national and regional applications in any country or territory in the world linked to the Patents, and the rights to all matter contained in such applications (the '**Further Applications**');
 - (iii) the right to file and prosecute divisional applications, continuations and continuations-in-part of the Patents and all Further Applications (the '**Divisional Applications**'); and
 - (iv) the absolute entitlement to any patents granted pursuant to the Patents, Further Applications and Divisional Applications for their full period, including any re-issues, re-examinations renewals, extensions and Supplementary Protection Certificates; and

Schedule: The Patents

country	Application number	Patent or Pub. No	Title/Invention
US	14/400,508	9,670,213	PTERIDINE KETONE DERIVATIVE AND APPLICATIONS THEREOF AS EGFR, BLK, AND FLT3 INHIBITOR
DE	112013002484.5	112013002484T5	PTERIDINE KETONE DERIVATIVE AND APPLICATIONS THEREOF AS EGFR, BLK, AND FLT3 INHIBITOR
US	15/577,516	11306095	USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR
CA	2,887,400	2887465	USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR
AU	2016272057	2016272057	USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR

(b) The right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions, the Patents and any patents granted on any of the applications filed as aforesaid in sub-clause (a), whether occurring before, on or after the date of this Assignment.

2. Further assurance


At the Assignee's expense, the Assignor will promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

3. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed will constitute a duplicate original, but all the counterparts will together constitute the one Assignment.

This Assignment has been entered into on the final signature date below.

Signed by  (print name), director or authorised representative, for and on behalf of
EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

 Fuzhen Xuan
Signature of director or authorised representative

Date: Oct. 25, 2022

Signed by Yuhu ZHANG
(print name), director or authorised representative, for and on behalf of
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Yuhu ZHANG
Signature of director or authorised representative

Date: Oct. 20, 2022